Skip to main content
Publications
Wainberg ZA, Enzinger PC, Qin S, Yamaguchi K, Wang J, Zhou X, Gnanasakthy A, Taylor K, Yusuf A, Maher I, Jamotte A, Kang Y-K. Health-related quality of life with bemarituzumab plus mFOLFOX6 in patients with FGFR2b-overexpressing, advanced gastric or gastroesophageal junction cancer. ESMO gastrointestinal oncology. 2024 Dec;6. doi: 10.1016/j.esmogo.2024.100095
Neofytos D, Pagliuca A, Houghton K, Broughton E, de Figueiredo Valente MLN, Jiang L, Enoch DA, Gruener B, Herbrecht R, Lahmer T, Lortholary O, Melenotte C, De Rosa FG, Garcia-Vidal C, Jimenez M, Fernandez M, Cornely O. Effectiveness, safety, and patterns of real-world isavuconazole use in Europe (2015-2019). Infect Dis Ther. 2024 Dec;13(12):2527-43. doi: 10.1007/s40121-024-01064-4
Weber J, Haque W, Markovic SN, Salama AKS, Mehmi I, Sullivan RJ, Najjar YG, van Akkooi ACJ, Menzies AM, Long GV, Taylor AM, Haanen J, Zijlker LP, Davis KL, Karanth S, Norton D, Connolly L. Relapse-free survival with adjuvant dabrafenib/trametinib therapy after relapse on a prior adjuvant CPI in BRAF V600-mutated stage III/IV melanoma. Oncologist. 2024 Nov 19. doi: 10.1093/oncolo/oyae289
Desai A, Dong OM, Gautier S, Johnson T, Wong A, Osman AMY, Harvey J, Tran TH, Holladay Ford DM, Kerr KW, Aggarwal A, Mauskopf J. A systematic review of health economic evaluations of oral nutritional supplements as a single-component or multi-component intervention in older adults with or at risk of malnutrition. Poster presented at the ISPOR Europe 2024; November 18, 2024. Barcelona, Spain.
Neches V, Campbell K, Coll P, Moreno Guillen S, Martinez-Sesmero JM, Lopez Segui F, O'Brien P, Davis A, Anderson SJ, Schroeder M, Vallejo-Aparicio LA. Cost-effectiveness of cabotegravir long-acting for pre-exposure prophylaxis versus current use of daily oral tenofovir disoproxil fumarate/emtricitabine or no prep to prevent HIV-1 in individuals at high risk in Spain. Poster presented at the ISPOR Europe 2024; November 17, 2024. Barcelona, Spain.
Rao S, McQuay L, Forns J, MacKay R, Aquilina T, Doshi D, Abler V, Anthony MS, Layton B. Mortality in patients with Parkinson's disease psychosis using pimavanserin versus other antipsychotics. Poster presented at the Neuroscience Education Institute (NEI) Congress 2024; November 8, 2024. Colorado Springs, CO.
Clemmet T, Basarir H, Buompensiere MI, Chrastecka N, de Portu S, Dias RP, Dunne JL, del Pozo CH, Mader JK, Narendran P, Nicholls C, Alsaleh AJO, Piemonti L, Vercauteren J, Mahieu A. Economic evaluations of screening in pre-symptomatic type 1 diabetes (T1D): a systematic literature review. Poster presented at the Immunology of Diabetes (IDS) Congress 2024; November 4, 2024. Bruges, Belgium.
Adelakun A, Dolph M, Matthews E, Oglebsy A, Campbell K, Davis A, Xu J, Hardy I, Danchenko N, Anderson SJ. Cost-effectiveness and public-health impact of cabotegravir long-acting injectable for HIV pre-exposure prophylaxis in Canada. Poster presented at the HIV Drug Therapy Glasgow 2024; November 10, 2024. Glasgow, Scotland. [abstract] J Int AIDS Soc. 2024 Nov; 27:234-5.
Rao S, McQuay L, Forns J, MacKay R, Aquilina T, Doshi D, Abler V, Anthony MS, Layton B. Comparing the mortality risk of patients on FDA-approved treatment for Parkinson's disease psychosis, pimavanserin, vs other antipsychotics. Poster presented at the 37th Annual Psych Congress; October 29, 2024. Boston, MA. Previously presented at the Neuroscience Education Institute (NEI) Congress 2024.
Chapman KR, Guyot P, Ledanois O, Soliman M, Wang Z, Xu Y, Nangia A, Cheng W-H. Efficacy of dupilumab versus tezepelumab in asthma patients: matching-adjusted indirect comparison of long-term extension trials. Poster presented at the American College of Allergy, Asthma & Immunology (ACAAI) 2024 Annual Scientific Meeting; October 25, 2024. Boston, MA.
